

G1070-2

IN THE UNITED STATES PATENT & TRADEMARK OFFICE



THE COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, DC 20231

Dear Sir:

Transmitted herewith for filing is the PATENT APPLICATION of:

Inventor(s): Kenneth William Batchelor; Stephen Vernon Frye;
George F. Dorsey, Jr.; Robert A. Mook, Jr.


Title: **ANDROSTENONE DERIVATIVE**

1. This is an application for an original invention, which is a continuation-in-part (CIP).
2. The new application being transmitted claims the benefit of prior International Application which designated the US and was filed 16 September 1994 as of PCT/US94/10530.
3. The oath or declaration executed by inventors
 is attached.
 will follow (an unsigned oath and Power of Attorney is attached.)
4. Enclosed are -0- sheets of drawings.
5. The inventorship for all the claims in this application are:
 the same
 are not the same. An explanation, including the ownership of the various claims at the time the last claimed invention was made,
 is submitted
 will be submitted
6. An assignment of the invention to Glaxo, Inc., Research Triangle Park, North Carolina
 is attached with separate cover letter and fee authority.
 will follow
7. A Certified copy of application was filed in
PCT/US94/10530 filed 16 September 1994
from which priority is claimed.
8. The filing fees have been calculated as shown below:

<u>For</u>	<u>No. Filed</u>	<u>No. Extra</u>	<u>Rate</u>	<u>Fee</u>
Basic Fee				\$730
Total Claims	24 -20	4	x 22	= \$ 88
Indep Claims	3 - 3	0	x 76	= \$ --
Multiple Dependency Claims			+ 240	= --
			TOTAL	\$ 818

If the difference in Col. 1 is less than zero, enter "0" in Col. 2.

G1070-2



9. The ~~Commissioner~~ is hereby authorized to charge payment of the following fees to Deposit Account No. 07-1392. A duplicate copy of this sheet is enclosed. Please charge as follows:

XX Filing Fee

\$818.00

TOTAL \$ 818.00


10. The Commissioner is hereby authorized to charge payment of the following additional fees during the pendency of this application or credit any overpayment to Deposit Account No. 07-1392:

- a. X Any patent application processing fees under 37 CFR 1.17.
- b. The issue fee set in 37 CFR 1.18 at or before mailing of the Notice of Allowance pursuant to 37 CFR 1.311(b).
- c. X Any filing fees under 37 CFR 1.16 for presentation of extra claims.

11. Address all correspondence to Charles E. Dadswell, Glaxo Inc., Five Moore Drive, Research Triangle Park, North Carolina 27709.

12. I hereby declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.


Date: March 16, 1995
Glaxo Inc.
Research Triangle Park,
North Carolina 27709


Charles E. Dadswell
Attorney for Applicant(s)
Registration No. 35,851
Telephone No: (919) 990-6983

CERTIFICATE OF MAILING (37 CFR 1.10)
Express Mail No. TB494703044 US sent 16 March 1995

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as express mail in an envelope addressed to the: Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Date: 16 March 1995


Rosalie Germano

G1070-2

Incorporation by reference of added pages:

Plus Added Pages For New Application Transmittal Where
Benefit of Prior International Application



Relate Back--35 USC 120

End the specification by inserting before the first line the sentence: "This is a

continuation-in-part
of copending application

International Application PCT/US94/10530 filed on 16 September 1994 and which designated the US."

14. Relate Back--35 USC 120 Priority Claim for Prior Application

The prior International Application designating the US, identified in item 12, in turn itself claims priority as follows:

<u>US</u>	<u>USSN 08/123,280</u>	<u>Filed: 17 September 1993</u>	<u>Abandoned</u>
country	appl. no.	filed on	status

The certified copy has been filed 10 November 1994 in International Application PCT/US94/10530 filed on 16 Sept 1994.

15. Inventorship Statement Where Benefit of Prior Appln(s) Claimed

 the same

are not the same.. An explanation, including the ownership of the various claims at the time the last claimed invention was made,

 is submitted

will be submitted

This transmittal ends with this page.